Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- SLGL
- Price
- 0.43
- Stock movement up
- +0.02 (4.88%)
- Company name
- Sol Gel Technologies Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 11.98M
- Ent value
- 6.83M
- Price/Sales
- 1.02
- Price/Book
- 0.35
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -11.01%
- 1 year return
- -48.61%
- 3 year return
- -60.88%
- 5 year return
- -42.65%
- 10 year return
- -
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
SLGL does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.02 |
| Price to Book | 0.35 |
| EV to Sales | 0.58 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 27.86M |
| EPS (TTM) | -0.34 |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 11.71M |
| Gross profit (TTM) | -247.00K |
| Operating income (TTM) | -11.36M |
| Net income (TTM) | -9.57M |
| EPS (TTM) | -0.34 |
| EPS (1y forward) | -0.47 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -2.11% |
| Operating margin (TTM) | -97.07% |
| Profit margin (TTM) | -81.75% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 13.42M |
| Net receivables | 7.02M |
| Total current assets | 37.95M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 42.98M |
| Accounts payable | 1.52M |
| Short/Current long term debt | 1.31M |
| Total current liabilities | 6.53M |
| Total liabilities | 8.28M |
| Shareholder's equity | 34.70M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 0.00 |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | 0.00 |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -27.58% |
| Return on Assets | -22.27% |
| Return on Invested Capital | -27.27% |
| Cash Return on Invested Capital | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.42 |
| Daily high | 0.43 |
| Daily low | 0.41 |
| Daily Volume | 19K |
| All-time high | 17.15 |
| 1y analyst estimate | 5.00 |
| Beta | 1.60 |
| EPS (TTM) | -0.34 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 19 May 2025 |
Downside potential
Loading...
Downside potential data
| SLGL | S&P500 | |
| Current price drop from All-time high | -97.49% | -12.89% |
| Highest price drop | -97.87% | -56.47% |
| Date of highest drop | 9 Aug 2024 | 9 Mar 2009 |
| Avg drop from high | -59.12% | -11.07% |
| Avg time to new high | 602 days | 12 days |
| Max time to new high | 1328 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
11.98M
Marketcap category
Small-cap
Description
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Employees
36
Website
Investor relations
-
SEC filings
CEO
Alon Seri-Levy
Country
USA
City
Ness Ziona
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page